Navigation Links
China Sky One Medical, Inc. Interviewed in The China Perspective
Date:12/5/2008

HARBIN, China, Dec. 5 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical took part in an insightful interview in today's issue of The China Perspective.

As a well-known pharmaceutical company in China, China Sky One was honored to receive an interview from The China Perspective, a leading source of China business news, research and analysis that provides insight into the trends, companies and industries that are shaping the Chinese economy. During the interview, Mr. Yan-Qing Liu spoke about the Company's recent acquisitions, its R&D capability and the impact of global financial crisis on pharmaceutical producers. For more information, please visit The China Perspective's website ( http://www.thechinaperspective.com ).

"This is an exciting time in the evolution of the pharmaceutical industry in China, and China Sky One is well positioned to offer insight as a leading drug manufacturer and distributor in China," commented Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We are thrilled to work with The China Perspective and to share our reflections about the global economic crisis and our expertise in the Chinese pharmaceutical market with the investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR''), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yubo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web site:http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... and development (R&D), today announced the launch of Data Science Services ... the rapidly evolving field of precision medicine. , Data Science Services ...
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, Inc. ... enhancing productivity in aquaculture and a majority-owned subsidiary of ... it has completed the listing of its common shares ... subscription from Intrexon. "AquaBounty,s listing on NASDAQ ... broaden our exposure to the U.S. markets as we ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... of drug and device development, and Prism Clinical Research , a leader ... announced Verified Clinical Trials (VCT) has been selected by both companies ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ... host a live webcast of its Annual Meeting of Shareholders on ... The webcast can be accessed from the BD corporate website at ... 31, 2017. ... About BD BD is a global medical technology company that ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)...   Avanade is helping Williams Martini Racing, ... history, exploit biometric data in order to critically analyse ... competitive edge against their rivals after their impressive, record-breaking ... has worked with Williams during the 2016 season to ... rate, breathing rate, temperature and peak acceleration) for key ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
Breaking Biology News(10 mins):